New drug combo shows promise for slowing kidney disease
NCT ID NCT05856760
First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tested whether adding the drug sparsentan to a standard SGLT2 inhibitor can safely reduce protein leakage in the urine of adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The 48 participants had already been on stable doses of both an SGLT2 inhibitor and another blood pressure medication for at least 12 weeks. The main goal was to see if the combination lowered urine protein levels after 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Travere Investigation Site
Clifton Park, New York, 12065, United States
-
Travere Investigational Site
Birmingham, Alabama, 35233, United States
-
Travere Investigational Site
Chula Vista, California, 91910, United States
-
Travere Investigational Site
Garden Grove, California, 92844, United States
-
Travere Investigational Site
Glendale, California, 91206, United States
-
Travere Investigational Site
Denver, Colorado, 80230, United States
-
Travere Investigational Site
Boise, Idaho, 83706, United States
-
Travere Investigational Site
Chubbuck, Idaho, 83202, United States
-
Travere Investigational Site
Idaho Falls, Idaho, 83404, United States
-
Travere Investigational Site
Chicago, Illinois, 60611, United States
-
Travere Investigational Site
Evergreen Park, Illinois, 60805, United States
-
Travere Investigational Site
Fort Wayne, Indiana, 46804, United States
-
Travere Investigational Site
Kansas City, Kansas, 66160, United States
-
Travere Investigational Site
Louisville, Kentucky, 40205, United States
-
Travere Investigational Site
Shreveport, Louisiana, 71101, United States
-
Travere Investigational Site
Albuquerque, New Mexico, 87109, United States
-
Travere Investigational Site
Fresh Meadows, New York, 11365, United States
-
Travere Investigational Site
New York, New York, 10013, United States
-
Travere Investigational Site
Jacksonville, North Carolina, 28546, United States
-
Travere Investigational Site
New Bern, North Carolina, 28562, United States
-
Travere Investigational Site
Columbus, Ohio, 43210, United States
-
Travere Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
Travere Investigational Site
Columbia, South Carolina, 29203, United States
-
Travere Investigational Site
Dallas, Texas, 75230, United States
-
Travere Investigational Site
Dallas, Texas, 75246, United States
-
Travere Investigational Site
Hong Kong, Hong Kong
-
Travere Investigational Site
Kowloon, Hong Kong
-
Travere Investigational Site
Shatin, Hong Kong
-
Travere Investigational Site
Sheung Wan, Hong Kong
-
Travere Investigational Site
Tsuen Wan, Hong Kong
Conditions
Explore the condition pages connected to this study.